Nimbus Therapeutics

Nimbus is applying deep computational chemistry expertise throughout the drug discovery and development process to create novel small molecules for substantial and underserved human diseases in metabolism, oncology and immunology. The company’s targets include emerging and well-validated targets that have proven intractable to others in the pharmaceutical and biotechnology industry, and its success has been reflected in the company’s high-profile partnerships with Gilead, Celgene, and Genentech.

Headquarters Cambridge, MA
Pipeline Preclinical & Clinical Programs
Partners Celgene, Genentech, Gilead, Monsanto, Schrödinger
Twitter @NimbusTx